A Blood-based Metabolite Signature for Personalized Risk Assessment of Pancreatic Cancer

Affiliations

¹ Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
² Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
³ Department of Translational Molecular Pathology and Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
⁴ Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis, Indiana, USA.
⁵ Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Comment

Ricardo A León-Letelier et al. J Cancer Immunol (Wilmington). 2024.

. 2024;6(4):148-153.

doi: 10.33696/cancerimmunol.6.095.

¹ Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
² Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
³ Department of Translational Molecular Pathology and Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
⁴ Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis, Indiana, USA.
⁵ Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA.

No abstract available

Figures

A blood-based metabolomic signature predictive of risk for pancreatic cancer.
Irajizad E, Kenney A, Tang T, Vykoukal J, Wu R, Murage E, Dennison JB, Sans M, Long JP, Loftus M, Chabot JA, Kluger MD, Kastrinos F, Brais L, Babic A, Jajoo K, Lee LS, Clancy TE, Ng K, Bullock A, Genkinger JM, Maitra A, Do KA, Yu B, Wolpin BM, Hanash S, Fahrmann JF. Irajizad E, et al. Cell Rep Med. 2023 Sep 19;4(9):101194. doi: 10.1016/j.xcrm.2023.101194. Cell Rep Med. 2023. PMID: 37729870 Free PMC article.

Patient-derived pancreatic tumor bacteria exhibit oncogenic properties and are recognized by MAIT cells in tumor spheroids.
Tajpara P, Sobkowiak MJ, Healy K, Naud S, Gündel B, Halimi A, Khan ZA, Gabarrini G, Le Guyader S, Imreh G, Reisz JA, Del Chiaro M, D'Alessandro A, Heuchel R, Löhr JM, Özenci V, Sällberg Chen M. Tajpara P, et al. Front Immunol. 2025 Apr 22;16:1553034. doi: 10.3389/fimmu.2025.1553034. eCollection 2025. Front Immunol. 2025. PMID: 40330456 Free PMC article.

1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49. - PubMed
1. Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated Projection of US Cancer Incidence and Death to 2040. JAMA Netw Open. 2021;4(4):e214708. - PMC - PubMed
1. Lippman SM, Abate-Shen C, Colbert Maresso KL, Colditz GA, Dannenberg AJ, Davidson NE, et al. AACR White Paper: Shaping the Future of Cancer Prevention - A Roadmap for Advancing Science and Public Health. Cancer Prev Res (Phila). 2018. Dec;11(12):735–78. - PMC - PubMed
1. Singhi AD, Koay EJ, Chari ST, Maitra A. Early Detection of Pancreatic Cancer: Opportunities and Challenges. Gastroenterology. 2019;156(7):2024–240. - PMC - PubMed
1. US Preventive Services Task Force; Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, et al. Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. 2019. Aug 6;322(5):438–44. - PubMed